SCHEMBL4415868

SCHEMBL4415868

COC(C(=O)O)C1CN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.45
USP2 O75604 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HPGD P15428 1/20 0.38
RORC P51449 1/20 0.38
GPR119 Q8TDV5 1/20 0.37
PDE4B Q07343 1/20 0.36
RECQL P46063 1/20 0.36
EPHX1 P07099 1/20 0.36
MMP1 P03956 3/20 0.36
MMP3 P08254 3/20 0.36
MMP7 P09237 3/20 0.36
MMP9 P14780 3/20 0.36
MMP8 P22894 3/20 0.36
MMP13 P45452 3/20 0.36
MMP2 P08253 2/20 0.36
DDB1 Q16531 1/20 0.36
CRBN Q96SW2 1/20 0.36
NAMPT P43490 1/20 0.36
USP30 Q70CQ3 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7288811 0.86 ALDH1A1 (0.47) USP2SMN1; SMN2HPGDGPR119PDE4B
SCHEMBL570862 0.80 NR1H2 (0.47) NR1H2USP2SMN1; SMN2HPGDRORC
SCHEMBL12179693 0.80 NR1H2 (0.47) NR1H2USP2SMN1; SMN2HPGDRORC
SCHEMBL23880037 0.78 NR1H2 (0.51) NR1H2USP2SMN1; SMN2HPGDRORC
SCHEMBL4546637 0.78 NR1H2 (0.51) NR1H2USP2SMN1; SMN2HPGDRORC
SCHEMBL3036029 0.76 NR1H2 (0.50) NR1H2USP2SMN1; SMN2HPGDGPR119
SCHEMBL10190233 0.76 NR1H2 (0.50) NR1H2USP2SMN1; SMN2HPGDRORC
SCHEMBL23485854 0.75 NR1H2 (0.50) NR1H2USP2SMN1; SMN2HPGDRORC
SCHEMBL12415380 0.75 NR1H2 (0.49) NR1H2USP2SMN1; SMN2HPGDRORC
SCHEMBL22470343 0.75 NR1H2 (0.57) NR1H2USP2SMN1; SMN2HPGDRORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325924-A1 GPCR Agonists GPR119, GCGR, GPR27 NR1H2 70/4885USP2 4077/4885SMN1; SMN2 2663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.